呼出气一氧化氮
哮喘
医学
生物标志物
炎症
一氧化氮
免疫学
单克隆抗体
疾病
内科学
抗体
生物化学
化学
支气管收缩
作者
Giovanni Rolla,Enrico Heffler,Stefano Pizzimenti,Alain Michils,Andreï Malinovschi
标识
DOI:10.2174/0929867327666200713184659
摘要
Asthma is a heterogeneous disease with regard to the inflammatory pathways activated. In recent years, biologic drugs (monoclonal antibodies) directed towards specific components of type 2 inflammation have been approved for the treatment of severe asthma. Phenotyping of patients with severe asthma and evaluation of biomarkers have been recommended to help identify patients who are candidates for treatment with biologics and to monitor treatment responses. Fractional exhaled Nitric Oxide (FeNO) is a biomarker of type 2 inflammation in asthma, signaling activation of Interleukin (IL)-4/IL-13 pathway. FeNO could be useful to assess treatment response or identify candidates for a specific drug that acts on type 2 inflammation mechanisms linked to Nitric Oxide (NO) production, such as the IL-4/IL-13 pathway or upstream processes. The value of FeNO as a biomarker predictive of responses to the biologics available for treating severe asthma is discussed based on the published studies at the moment of the review.
科研通智能强力驱动
Strongly Powered by AbleSci AI